iCAD (NASDAQ:ICAD) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

iCAD, Inc. (NASDAQ:ICAD)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.59 and traded as high as $1.97. iCAD shares last traded at $1.83, with a volume of 138,448 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

iCAD Stock Performance

The stock has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $1.59. The stock has a market cap of $48.57 million, a price-to-earnings ratio of -14.08 and a beta of 1.43.

Institutional Investors Weigh In On iCAD

An institutional investor recently bought a new position in iCAD stock. Essex LLC bought a new stake in iCAD, Inc. (NASDAQ:ICAD) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned approximately 0.52% of iCAD as of its most recent filing with the SEC. 24.61% of the stock is currently owned by institutional investors and hedge funds.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.